Gastrointestinal Agents Market By Drug Class (Antidiarrheal, Anti-Ulcers, Laxatives, Inflammatory Bowel Disease Irritable Bowel Syndrome) - Growth, Future Prospects And Competitive Analysis 2017 – 2025
Gastrointestinal (GI) symptoms generally include bloating, heartburn, indigestion/dyspepsia, and constipation. According to a new study, almost 74 percent of Americans suffer with digestive symptoms like gas, diarrhea, bloating and abdominal pain. In this study scope, gastrointestinal disease or disorder includes gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Among the considered conditions, incidence of GERD is the highest and commonly observed, followed by IBS and IBD. Thus rise in chronic gastrointestinal disorders and diseases, along with availability of OTC drugs are driving the growth of gastrointestinal drugs market.
The report titled “Gastrointestinal Agents Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall gastrointestinal agents market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global gastrointestinal agents market are majorly segmented into antidiarrheal, anti-ulcers, laxatives, inflammatory bowel disease drugs and irritable bowel syndrome drugs
Geographically, the global gastrointestinal agents market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gastrointestinal agents market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global gastrointestinal agents market. This report concludes with company profiles section that highlights major information about the key players engaged in global gastrointestinal agents market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Based on the type of drugs, the global gastrointestinal agents market is segmented as follows:
- Antidiarrheal
- Anti-emetics
- Anticholinergic Agents
- Antihistamines
- Serotonin 5-HT3 Receptor Antagonists
- Cannabinoid Receptor Agonists
- Anti-ulcers
- Histamine type 2 receptor blockers (H2 blockers)
- Proton Pump Inhibitors
- Laxatives
- Inflammatory bowel disease
- 5-Aminosalicyclic Acid (5-ASA) Derivatives
- Immunosuppressive Agents
- Tumor Necrosis Factor Antagonists
- Irritable bowel syndrome
- Antimuscarinics/Antispasmodics
- Prokinetic Agents
Medications for gastrointestinal diseases and symptoms include prescription and nonprescription drugs, conventional and unconventional agents, simple small molecules, complex macromolecules and large recombinant proteins. In base year 2016, the inflammatory bowel disease held the largest share in the gastrointestinal agents market due high prevalence of inflammatory bowel disease in the region. While, irritable bowel syndrome is anticipated to grow at the highest CAGR during the forecast period.
For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
At present, North America dominates the global gastrointestinal agents market. Particularly U.S. captures the largest market share in the regional gastrointestinal agents market. However, the region is expected to witness flat growth due to maturity of this market and no anticipated competition from potential drug. Europe is considered to be the second largest gastrointestinal agents market. Asia Pacific is anticipated to be the fastest growing market in the forecast period. Rising incidence of gastrointestinal disease and disorder, advancement in technology and overall improvement in health care infrastructure in emerging economies are the key drivers for Asia Pacific market.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I – Secondary Research
1.2.2 Phase II – Primary Research
1.2.3 Phase III – Expert Panel Review
1.2.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Gastrointestinal Agents Market Portraiture
2.2 Global Gastrointestinal Agents Market Revenue, by Class, 2016 Vs 2025 (Value %)
2.3 Global Gastrointestinal Agents Market Revenue, by Geography, 2016 (US$ Million)
Chapter 3 Global Gastrointestinal Agents Market Analysis
3.1 Global Gastrointestinal Agents Market Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Rise in the instances of gastrointestinal diseases and disorders
3.2.1.2 Active development in pipelines drugs and biologics
3.2.2 Challenges
3.2.2.1 Most of the patient prefers home remedies in its initial stage of diseases
3.2.3 Opportunities
3.2.3.1 Rise in used of OTC drugs and food supplements
3.3 Food Supplements as Supportive Therapy for Gastrointestinal Diseases (2015-2016) (US$)
3.4 Incidence Rate of GERD, IBD and IBS, 2016
3.5 Attractive Investment Proposition
3.6 Competitive Analysis: Key Players in Global Gastrointestinal Agents Market
Chapter 4 Gastrointestinal Agents Market Analysis, by Drug Class, 2015-2025 (US$ Mn)
4.1 Overview
4.2 Antidiarrheal
4.3 Anti-emetics
4.3.1 Anticholinergic Agents
4.3.2 Antihistamines
4.3.3 Serotonin 5-HT3 Receptor Antagonists
4.3.4 Cannabinoid Receptor Agonists
4.4 Anti-ulcers
4.4.1 Histamine type 2 receptor blockers (H2 blockers)
4.4.2 Proton Pump Inhibitors
4.5 Laxatives
4.6 Inflammatory bowel disease
4.6.1 5-Aminosalicyclic Acid (5-ASA) Derivatives
4.6.2 Immunosuppressive Agents
4.6.3 Tumor Necrosis Factor Antagonists
4.7 Irritable bowel syndrome
4.7.1 Antimuscarinics/Antispasmodics
4.7.2 Prokinetic Agents
Chapter 5 Americal Gastrointestinal Agents Market, by Geography, 2015-2025 (US$ Mn)
5.1 Overview
5.2 North Americ (USA and Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of Asia Pacific)
5.5 Latin America (Brazil, Mexico and Rest of Latin America)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa and Rest of Middle East and Africa)
Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Allergan Plc. (Formerly Actavis Plc.)
6.3 AstraZeneca
6.4 Bayer AG
6.5 Boehringer Ingelheim GmbH
6.6 GlaxoSmithKline plc.
6.7 Janssen Biotech, Inc.
6.8 Ranbaxy Laboratories Limited
6.9 Sanofi
6.10 Takeda Pharmaceutical
6.11 Valeant Pharmaceuticals, Inc.
TABLE 1 Food Supplements as Supportive Therapy for Gastrointestinal Diseases (2015-2016) (US$)
TABLE 2 Incidence rate of GERD, IBD and IBS, 2016
TABLE 3 Global Gastrointestinal Agents Market, by Drug Class, 2015 - 2025 (US$ Mn)
TABLE 4 Anti-emetics Global Gastrointestinal Agents Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 Anti-ulcers Global Gastrointestinal Agents Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Inflammatory Bowel Disease Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Global Irritable Bowel Disease Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 8 Global Gastrointestinal Agents Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 9 North America Gastrointestinal Agents Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Gastrointestinal Agents, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Gastrointestinal Agents, by Country, 2013 – 2024 (US$ Mn)
TABLE 12 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Allergan Plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 AstraZeneca: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Janssen Biotech, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Sanofi: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Takeda Pharmaceutical: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Valeant Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
FIG. 1 Global Gastrointestinal Agents Market: Research Methodology
FIG. 2 Global Gastrointestinal Agents Market Revenue, by Class, 2016 Vs 2025 (Value %)
FIG. 3 Global Gastrointestinal Agents Market Revenue, by Geography, 2016 (US$ Million)
FIG. 4 Attractive Investment Proposition: Global Gastrointestinal Agents Market
FIG. 5 Competitive Analysis: Key Players in Global Gastrointestinal Agents Market
FIG. 6 Antidiarrheal Market, 2015 – 2025 (US$ Mn)
FIG. 7 Anticholinergic Agents Market, 2015 - 2025 (US$ Mn)
FIG. 8 Antihistamine Agents Market, 2015 - 2025 (US$ Mn)
FIG. 9 Serotonin 5-HT3 Receptor Antagonists Market, 2015 - 2025 (US$ Mn)
FIG. 10 Cannabinoid Receptor Agonists Market, 2015 - 2025 (US$ Mn)
FIG. 11 Histamine Type 2 Receptor Blockers (H2 Blockers) Market, 2015 - 2025 (US$ Mn)
FIG. 12 Proton Pump Inhibitors Market, 2015 - 2025 (US$ Mn)
FIG. 13 Laxatives Market, 2015 - 2025 (US$ Mn)
FIG. 14 5-aminosalicylic Acid Derivatives Market, 2015 - 2025 (US$ Mn)
FIG. 15 Immunosuppressive Agents Market, 2015 - 2025 (US$ Mn)
FIG. 16 Tumor Necrosis Factor Antagonists Market, 2015 - 2025 (US$ Mn)
FIG. 17 Antimuscarinics/Antispasmodics Market, 2015 - 2025 (US$ Mn)
FIG. 18 Prokinetic Agents Market, 2015 - 2025 (US$ Mn)
FIG. 19 Latin America Gastrointestinal Agents, 2013 – 2024 (US$ Mn)
FIG. 20 Middle East & Africa Gastrointestinal Agents, 2013 – 2024 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)